First Washington Corp’s Acadia Pharmaceuticals ACAD Stock Holding History

First Washington Corp’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-264,760	Closed	-$4.04M	–	88
2018 Q2	$4.04M	Buy	264,760 +87,810	+50%	+$1.57M	2%	18
2018 Q1	$3.98M	Buy	176,950 +116,380	+192%	+$3.22M	2.06%	21
2017 Q4	$1.82M	Buy	+60,570	New	+$1.94M	0.86%	42

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Washington Corp's ACAD Position: Q3 2018 in Review

First Washington Corp sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 264,760 shares — an estimated $4.04M sold.

First Washington Corp first reported a position in ACAD in Q4 2017 and held it in 3 quarters. The position peaked at $4.04M in Q2 2018. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

First Washington Corp reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
First Washington Corp sold 264,760 Acadia Pharmaceuticals shares in Q3 2018, an estimated $4.04M.
First Washington Corp first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 3 quarters.
First Washington Corp's Acadia Pharmaceuticals position peaked at $4.04M in Q2 2018.
184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on First Washington Corp's 13F filing for Q3 2018, filed 13 Nov 2018.